Company Overview More
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
CEO: Ben-Asher, Dror
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

RDHL Redhill Biopharma Ltd

5.140+0.150+3.01%
Close 09/27 18:45 ET
5.14000.00%
Post Mkt Price 09/27 17:46 ET
High
5.150
Open
4.930
Turnover
5.30M
Low
4.930
Prev.Close
4.990
Volume
1.05M
Market Cap
239.87M
P/E(TTM)
Loss
52Wk High
11.520
Shares
46.67M
P/E
Loss
52Wk Low
4.480
H Mkt Cap
175.58M
Bid-Ask Ratio
-66.88%
Historical High
22.220
H Shares
34.16M
Vol. Ratio
1.62
Historical Low
3.262
Dividend TTM
--
Div Yield TTM
25
P/B
8.11
Dividend LFY
--
Div Yield LFY
486.38%
Turnover Ratio
3.07%
Amplitude
4.41%
Avg Price
5.057
Min Trading Unit
1
Float Market Cap
175.58M
Bid-Ask Ratio
-66.88%
Historical High
22.220
Float
34.16M
Vol. Ratio
1.62
Historical Low
3.262
Dividend TTM
--
P/B
8.11
Dividend LFY
--
Turnover Ratio
3.07%
Amplitude
4.41%
Avg Price
5.057
Min Trading Unit
1
Price Forecast

Loading...

News